Clinical trial
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell…
NCT00117988 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00117988 |
|---|---|
| Title | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma |
| Official title | A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | tanespimycin |
| Enrollment | 22 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jul 11, 2005 |
| Last update posted | May 30, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: